Lancet Neurology publishes landmark paper of a potential therapy for ALS developed in collaboration with UCSD and Isis Pharmaceutical Co: "An Antisense Oligonucleotide against SOD1 Delivered Intrathecally for Patients with SOD1-Familial Amyotrophic Lateral Sclerosis: a phase 1, randomized, first-in man study."
top of page
bottom of page